No association between vedolizumab exposure and serum JC virus levels.
A. Parikh(Takeda (United States)), Catherine Milch(Millennium Engineering and Integration (United States)), Eric R. Fedyk(Takeda (United States)), Joseph R. Berger(University of Pennsylvania), Serap Sankoh(Millennium Engineering and Integration (United States)), James S. Paolino(Takeda (United States)), David B. Clifford(Washington University in St. Louis), Irving H. Fox(Takeda (United States))
Cited by 4
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
|New England Journal of Medicine|2006|792